Management and dosing of warfarin therapy

被引:116
作者
Gage, BF
Fihn, SD
White, RH
机构
[1] Washington Univ, Sch Med, Div Gen Med Sci, St Louis, MO 63110 USA
[2] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[4] Univ Calif Davis, Div Gen Med, Sacramento, CA 95817 USA
关键词
D O I
10.1016/S0002-9343(00)00545-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
When initiating warfarin therapy, clinicians should avoid loading doses-that can raise the International Normalized Ratio (INR) excessively; instead, warfarin should be initiated with a 5-mg dose (or 2 to 4 mg in the very elderly). With a 5-mg initial dose, the INR will not rise appreciably in the first 24 hours, except in rare patients who will ultimately require a very small daily dose (0.5 to 2.0 mg). Adjusting a steady-slate warfarin dose depends on the measured INR values and clinical factors: the dose does not need to be adjusted for a single INR that is slightly out of range, and most changes should alter the total weekly dose by 5% to 20%. The INR should be monitored frequently (eg, 2 to 4 times per week) immediately after initiation of warfarin; subsequently, the interval between INR tests can be lengthened gradually (up to a maximum of 4 to 6 weeks) in patients with Stable INR values. Patients who have an elevated INR will need more frequent testing and may also require vitamin K1. For example, a nonbleeding patient with an INR of 9 can be given low-dose vitamin K1 (eg, 2.5 mg phytonadione, by mouth). Patients who have an excessive INR with clinically important bleeding require clotting factors leg, fresh-frozen plasma) as well as vitamin K1. Am J Med. 2000;109:481-488. (C) 2000 by Excerpta Medica, Inc.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 106 条
[1]   A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy [J].
Ageno, W ;
Turpie, AGG .
THROMBOSIS RESEARCH, 1998, 91 (05) :237-240
[2]   EVALUATION OF A PORTABLE PROTHROMBIN TIME MONITOR FOR HOME-USE BY PATIENTS WHO REQUIRE LONG-TERM ORAL ANTICOAGULANT-THERAPY [J].
ANDERSON, DR ;
HARRISON, L ;
HIRSH, J .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (12) :1441-1447
[3]   Consensus guidelines for coordinated outpatient oral anticoagulation therapy management [J].
Ansell, JE ;
Buttaro, ML ;
Thomas, IV ;
Knowlton, CH ;
Becker, DM ;
Bussey, HI ;
Corey, R ;
Gums, JG ;
Hughes, R ;
Jacobson, A ;
Kirchain, W ;
Kuhn, K ;
Loken, S ;
McCain, J ;
Haley, JA ;
Oertel, LB ;
Thrasher, K ;
Triplett, DA ;
Whitcomb, H ;
Wittkowsky, AK ;
Zarus, SA .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (05) :604-615
[4]   LONG-TERM PATIENT SELF-MANAGEMENT OF ORAL ANTICOAGULATION [J].
ANSELL, JE ;
PATEL, N ;
OSTROVSKY, D ;
NOZZOLILLO, E ;
PETERSON, AM ;
FISH, L .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (20) :2185-2189
[5]   Determinants of compliance with anticoagulation: A case-control study [J].
Arnsten, JH ;
Gelfand, JM ;
Singer, DE .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (01) :11-17
[6]   Optimal intensity of oral anticoagulant therapy after myocardial infarction [J].
Azar, AJ ;
Cannegieter, SC ;
Deckers, JW ;
Briet, E ;
vanBergen, PFMM ;
Jonker, JJC ;
Rosendaal, FR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (06) :1349-1355
[7]   INVESTIGATION OF PATIENTS WITH ABNORMAL RESPONSE TO WARFARIN [J].
BENTLEY, DP ;
BACKHOUSE, G ;
HUTCHINGS, A ;
HADDON, RL ;
SPRAGG, B ;
ROUTLEDGE, PA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) :37-41
[8]  
BEYTH RJ, 2000, IN PRESS ANN INTERN
[9]  
BJORNSSON TD, 1978, LANCET, V2, P846
[10]  
Brigden ML, 1998, AM J HEMATOL, V59, P22, DOI 10.1002/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.3.CO